The average price point forecasted by analysts for Travere Therapeutics Inc (TVTX) is $14.33, which is $8.43 above the current market price. The public float for TVTX is 70.99M, and currently, short sellers hold a 12.40% ratio of that float. The average trading volume of TVTX on November 21, 2023 was 1.81M shares.
TVTX) stock’s latest price update
Travere Therapeutics Inc (NASDAQ: TVTX) has experienced a rise in its stock price by 2.61 compared to its previous closing price of 5.75. However, the company has seen a fall of -3.12% in its stock price over the last five trading days. Seeking Alpha reported 2023-11-07 that Travere Therapeutics, Inc. (NASDAQ:TVTX ) Q3 2023 Results Conference Call November 7, 2023 4:30 PM ET Company Participants Naomi Eichenbaum – Vice President-Investor Relations Dr. Eric Dube – Chief Executive Officer Dr. Jula Inrig – Chief Medical Officer Peter Heerma – Chief Commercial Officer Chris Cline – Chief Financial Officer Dr. Bill Rote – Senior Vice President of Research & Development Conference Call Participants Anupam Rama – JP Morgan Maury Raycroft – Jefferies Greg Harrison – Bank of America Vamil Divan – Guggenheim Securities Liisa Bayko – Evercore.ISI Edwin Delfin – Barclays Laura Chico – Wedbush Securities Alex Thompson – Stifel Allison Bratzel – Piper Sandler Ed Arce – H.C. Wainwright & Company Operator Good day, and welcome to the Travere Therapeutics Third Quarter 2023 Financial Results and Corporate Update Conference Call.
TVTX’s Market Performance
TVTX’s stock has fallen by -3.12% in the past week, with a monthly drop of -16.07% and a quarterly drop of -53.62%. The volatility ratio for the week is 6.39% while the volatility levels for the last 30 days are 7.24% for Travere Therapeutics Inc The simple moving average for the past 20 days is -8.02% for TVTX’s stock, with a -61.87% simple moving average for the past 200 days.
Analysts’ Opinion of TVTX
Many brokerage firms have already submitted their reports for TVTX stocks, with Citigroup repeating the rating for TVTX by listing it as a “Neutral.” The predicted price for TVTX in the upcoming period, according to Citigroup is $7 based on the research report published on November 20, 2023 of the current year 2023.
TVTX Trading at -26.37% from the 50-Day Moving Average
After a stumble in the market that brought TVTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -74.55% of loss for the given period.
Volatility was left at 7.24%, however, over the last 30 days, the volatility rate increased by 6.39%, as shares sank -21.30% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -58.00% lower at present.
During the last 5 trading sessions, TVTX fell by -4.75%, which changed the moving average for the period of 200-days by -73.75% in comparison to the 20-day moving average, which settled at $6.34. In addition, Travere Therapeutics Inc saw -71.94% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at TVTX starting from Heerma Peter, who sale 3,091 shares at the price of $8.25 back on Oct 03. After this action, Heerma Peter now owns 80,257 shares of Travere Therapeutics Inc, valued at $25,504 using the latest closing price.
Dube Eric M, the Chief Executive Officer of Travere Therapeutics Inc, sale 4,455 shares at $14.71 during a trade that took place back on Sep 05, which means that Dube Eric M is holding 242,595 shares at $65,533 based on the most recent closing price.
Stock Fundamentals for TVTX
Current profitability levels for the company are sitting at:
- -118.65 for the present operating margin
- +80.82 for the gross margin
The net margin for Travere Therapeutics Inc stands at -131.35. The total capital return value is set at -49.60, while invested capital returns managed to touch -55.36. Equity return is now at value -171.92, with -41.95 for asset returns.
Based on Travere Therapeutics Inc (TVTX), the company’s capital structure generated 950.94 points at debt to equity in total, while total debt to capital is 90.48. Total debt to assets is 60.59, with long-term debt to equity ratio resting at 940.60. Finally, the long-term debt to capital ratio is 89.50.
When we switch over and look at the enterprise to sales, we see a ratio of 1.89, with the company’s debt to enterprise value settled at 0.31. The receivables turnover for the company is 12.93 and the total asset turnover is 0.29. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.42.
To put it simply, Travere Therapeutics Inc (TVTX) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.